SCHEMBL13623152

SCHEMBL13623152

CC(C)(C)OC(=O)Nc1cccc(CCO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
TRPV1 Q8NER1 1/20 0.49
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
AURKA O14965 1/20 0.48
RPS6KB1 P23443 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.47
HDAC6 Q9UBN7 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
CYP17A1 P05093 2/20 0.46
SIRT1 Q96EB6 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30844047 1.00 CYP3A4 (0.50) CYP3A4CYP2C19TRPV1CYP4F2CYP4A11
SCHEMBL7972399 0.92 CYP3A4 (0.48) CYP3A4CYP2C19CYP4F2CYP4A11AURKA
SCHEMBL6691001 0.89 CYP4F2 (0.51) CYP3A4CYP2C19CYP4F2CYP4A11AURKA
SCHEMBL27498370 0.89 CYP3A4 (0.50) CYP3A4CYP2C19AURKARPS6KB1SIRT2
SCHEMBL13801959 0.89 CYP3A4 (0.50) CYP3A4CYP2C19AURKARPS6KB1SIRT2
SCHEMBL7156537 0.89 MGLL (0.52) CYP3A4CYP2C19AURKARPS6KB1SIRT2
SCHEMBL1858721 0.88 PDK1 (0.58) CYP3A4CYP2C19AURKARPS6KB1SIRT2
SCHEMBL31139332 0.88 PDK1 (0.58) CYP3A4CYP2C19AURKARPS6KB1SIRT2
SCHEMBL20132327 0.88 PDK1 (0.49) CYP3A4CYP2C19AURKARPS6KB1SIRT2
SCHEMBL31370757 0.87 AURKA (0.50) CYP3A4CYP2C19AURKARPS6KB1SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125417-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2026-05-07 US disclosed
EP-4590686-A1 GLUCOCORTICOID RECEPTOR AGONISTS Eli Lilly and Company (US) 2025-07-30 EP disclosed
WO-2024064779-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2024-03-28 WO disclosed
EP-3298011-B1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2021-11-17 EP disclosed
US-20180155340-A1 QUINOLONE DERIVATIVES AS FGFR INHIBITORS PRINCIPIA BIOPHARMA INC. 2018-06-07 US disclosed
EP-2994470-B1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2018-04-18 EP disclosed
EP-3298011-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-03-28 EP disclosed
US-9630963-B2 Quinolone derivatives as fibroblast growth factor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-04-25 US disclosed
WO-2016191172-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-01 WO disclosed
US-20160130268-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2016-05-12 US disclosed
EP-2994470-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS Principia Biopharma Inc. (US) 2016-03-16 EP disclosed
WO-2014182829-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-11-13 WO disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK CYP3A4 3025/4885CYP2C19 2221/4885TRPV1 1707/4885
US-20180155340-A1 QUINOLONE DERIVATIVES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CYP3A4 1825/4885CYP2C19 1410/4885TRPV1 4462/4885
US-20260125417-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R CYP3A4 2119/4885CYP2C19 1427/4885TRPV1 279/4885
US-20160130268-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS FGFR1, FGFR3, FGFR2 CYP3A4 1506/4885CYP2C19 1100/4885TRPV1 4403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.